Skip to content

The effects of pomegranate seed (PSO) with resistance exercise on insulin resistance and cardiovascular risk factors in non-athletic men

The effects of pomegranate seed (PSO) with resistance exercise on insulin resistance and cardiovascular risk factors in non-athletic men

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016092730023N1
Enrollment
14
Registered
2017-02-10
Start date
2016-12-10
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Obesity

Interventions

Intervention 1: 400 mg doses of 2 capsules of pomegranate seed oil + RT. Intervention 2: 2 + placebo control group resistance training.
Treatment - Drugs
400 mg doses of 2 capsules of pomegranate seed oil + RT
2 + placebo control group resistance training

Sponsors

Rajai Teacher Training University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
21 Years to 23 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Healthy young men with no previous record of any specific drug use? without experience of regular physical activity in two year before beginning of the study. Exclusion Criteria: Unhealthy? Doing regular exercise during the last two years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting insulin. Timepoint: Before and after 4 weeks. Method of measurement: Elisa.

Secondary

MeasureTime frame
Lipid profiles (total cholesterol, triglycerides, and low high-density cholesterol). Timepoint: Before and after 4 weeks. Method of measurement: Enzymatic.;Insulin resistance index. Timepoint: Before and after 4 weeks. Method of measurement: Elisa.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhalil ollah Moonikh

Rajai Teacher Training University

kh.moonikh@gmail.com+98 21 2297 0060

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026